Delcath Systems Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Delcath Systems wird ein Gewinn- und Umsatzwachstum von 71.2% bzw. 41.6% pro Jahr prognostiziert, während der Gewinn pro Aktie um 73% pro Jahr wachsen soll.

Wichtige Informationen

71.2%

Wachstumsrate der Gewinne

73.0%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	17.1%
Wachstumsrate der Einnahmen	41.6%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	12 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Delcath Systems: Q3 Earnings Reveal HEPZATO KIT And CHEMOSAT Growth

Nov 18

Delcath Systems, Inc.'s (NASDAQ:DCTH) P/S Is Still On The Mark Following 26% Share Price Bounce

Nov 01

Delcath Systems, Inc.'s (NASDAQ:DCTH) 26% Jump Shows Its Popularity With Investors

Sep 10

Is Delcath Systems (NASDAQ:DCTH) A Risky Investment?

Aug 27

Delcath Systems, Inc. (NASDAQ:DCTH) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Aug 07

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:DCTH - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	134	29	34	47	6
12/31/2025	73	-7	-2	14	6
12/31/2024	35	-24	-18	-16	6
9/30/2024	23	-34	-26	-26	N/A
6/30/2024	12	-56	-32	-31	N/A
3/31/2024	5	-50	-37	-37	N/A
12/31/2023	2	-48	-31	-31	N/A
9/30/2023	2	-45	-30	-30	N/A
6/30/2023	3	-34	-27	-26	N/A
3/31/2023	3	-37	-23	-23	N/A
12/31/2022	3	-37	-25	-25	N/A
9/30/2022	4	-33	-24	-24	N/A
6/30/2022	4	-32	-24	-23	N/A
3/31/2022	4	-28	-25	-24	N/A
12/31/2021	4	-26	-23	-23	N/A
9/30/2021	2	-27	-22	-22	N/A
6/30/2021	2	-25	-22	-21	N/A
3/31/2021	2	-23	-23	-22	N/A
12/31/2020	2	-24	-24	-23	N/A
9/30/2020	2	-5	-24	-23	N/A
6/30/2020	2	-7	-31	-31	N/A
3/31/2020	2	-9	-26	-26	N/A
12/31/2019	2	-9	-24	-24	N/A
9/30/2019	2	-32	-20	-20	N/A
6/30/2019	3	-34	-11	-11	N/A
3/31/2019	3	-34	-11	-11	N/A
12/31/2018	3	-19	-15	-15	N/A
9/30/2018	3	-28	-17	-17	N/A
6/30/2018	3	-32	N/A	-17	N/A
3/31/2018	3	-27	N/A	-18	N/A
12/31/2017	3	-46	N/A	-15	N/A
9/30/2017	3	-34	N/A	-15	N/A
6/30/2017	2	-23	N/A	-15	N/A
3/31/2017	2	-27	N/A	-14	N/A
12/31/2016	2	-18	N/A	-14	N/A
9/30/2016	2	-15	N/A	-15	N/A
6/30/2016	2	-16	N/A	-14	N/A
3/31/2016	2	-13	N/A	-16	N/A
12/31/2015	2	-15	N/A	-16	N/A
9/30/2015	2	-13	N/A	-15	N/A
6/30/2015	1	-15	N/A	-16	N/A
3/31/2015	1	-16	N/A	-15	N/A
12/31/2014	1	-17	N/A	-16	N/A
9/30/2014	1	-19	N/A	-18	N/A
6/30/2014	1	-22	N/A	-21	N/A
3/31/2014	1	-23	N/A	-28	N/A
12/31/2013	1	-30	N/A	-34	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: DCTH wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.6%).

Ertrag vs. Markt: DCTH wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: DCTH wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: DCTHDie Einnahmen des Unternehmens (41.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: DCTHDie Einnahmen des Unternehmens (41.6% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von DCTH in 3 Jahren voraussichtlich hoch sein wird

Delcath Systems Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus estimates of losses per share improve by 35%

Forecast breakeven date moved forward to 2025

Forecast breakeven date moved forward to 2025

Consensus EPS estimates fall by 14%

Consensus revenue estimates increase by 13%

Recent updates

Delcath Systems: Q3 Earnings Reveal HEPZATO KIT And CHEMOSAT Growth

Consensus estimates of losses per share improve by 35%

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Forecast breakeven date moved forward to 2025

Delcath Systems, Inc.'s (NASDAQ:DCTH) P/S Is Still On The Mark Following 26% Share Price Bounce

CEO & Director exercised options to buy US$177k worth of stock.

Forecast breakeven date moved forward to 2025

Delcath Systems, Inc.'s (NASDAQ:DCTH) 26% Jump Shows Its Popularity With Investors

Consensus EPS estimates fall by 14%

Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients

Is Delcath Systems (NASDAQ:DCTH) A Risky Investment?

Consensus revenue estimates increase by 13%

Delcath Systems, Inc. (NASDAQ:DCTH) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Delcath Systems Regains Compliance with the Audit Committee Composition Requirements

Delcath Systems, Inc. Appoints Bridget Martell to Board of Directors

New major risk - Financial position

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Consensus revenue estimates increase by 11%

Price target increased by 8.1% to US$20.80

Delcath Systems, Inc. to Report Q1, 2024 Results on May 14, 2024

Delcath Systems, Inc Announces Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT

Delcath Systems, Inc., Annual General Meeting, May 23, 2024

Forecast breakeven date pushed back to 2026

Delcath Systems, Inc. to Report Q4, 2023 Results on Mar 26, 2024

Delcath Systems, Inc. Appoints Martha S. Rook as Chief Operating Officer

Delcath Systems, Inc. Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System)

Delcath Systems, Inc. Announces Executive Changes

Delcath Systems Receives Permanent J-Code (J9248) for HEPZATO™ (melphalan/Hepatic Delivery System) Effective April 1, 2024

Delcath Systems Announces U.S. Launch and First Commercial Treatment Utilizing Hepzato Kit™

Is Delcath Systems (NASDAQ:DCTH) Using Debt In A Risky Way?

No longer forecast to breakeven

CEO & Director recently bought US$100k worth of stock

Chief Medical Officer recently bought US$149k worth of stock

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 34%

Insufficient new directors

Delcath Systems (NASDAQ:DCTH) Has Debt But No Earnings; Should You Worry?

Consensus revenue estimates fall by 18%

Independent Chairman recently bought US$51k worth of stock

CEO & Director exercised options to buy US$171k worth of stock.

Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma

Price target increased by 11% to US$18.20

Consensus EPS estimates upgraded to US$1.92 loss

New major risk - Shareholder dilution

No longer forecast to breakeven

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Delcath Systems, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Delcath Systems Appoints Vojislav Vukovic as Chief Medical Officer

Delcath Systems, Inc. Appoints Sandra Pennell as Senior Vice President of Finance

Delcath Systems, Inc. Provides Preliminary Earnings Guidance for the First Quarter Ended March 31, 2023

Consensus revenue estimates decrease by 46%, EPS upgraded

Full year 2022 earnings: EPS and revenues miss analyst expectations

Delcath Systems, Inc. Announces Board Changes

Delcath Systems, Inc. Announces New Drug Application Resubmission for HEPZATO Kit

Delcath Systems Announces Updated Results from Chopin Phase 1B Trial Published in Cardiovascular and Interventional Radiology

Forecast to breakeven in 2025

Independent Director recently bought US$55k worth of stock

Delcath Systems, Inc. announced that it has received $6.201779 million in funding

Delcath Systems, Inc. Announces Results of Single Center Study on Delcath's CHEMOSAT Hepatic Delivery System in the Treatment of Cholangiocarcinoma Published in the Journal Clinical & Experimental Metastasis

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$18.20

Delcath Systems, Inc. Receives Non-Compliance Letter from Nasdaq

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Results of A Multicenter Study on Delcath's Chemosat Hepatic Delivery System Published in Cardiovascular and Interventional Radiology

Delcath Systems Q2 2022 Earnings Preview

CEO & Director recently bought US$250k worth of stock

Delcath Systems, Inc. announced that it has received $4.999998 million in funding

Delcath Systems, Inc. announced that it expects to receive $5.000038 million in funding